Skip to search formSkip to main contentSkip to account menu

BMY 28090

Known as: BMY-28090, BMY28090 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

elsamicin A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Validated HPLC procedures for the analysis of BMY-28090 in human plasma and urine
SummaryThe compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone… 
2004
2004
Phase II study of elsamitrucin in non-small cell lung cancer
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell… 
1993
1993
Determination of Elsamitrucin (BMY-28090) in plasma and urine by high-performance liquid chromatography with fluorescence detection.
1992
1992
Phase I trial and clinical pharmacology of elsamitrucin.
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)